The role of phonophoresis in patients with COPD: a randomized clinical trial

M. Shen (changchun, China)

Source: Virtual Congress 2020 – Clinical and basic pharmacology for COPD
Session: Clinical and basic pharmacology for COPD
Session type: E-poster session
Number: 176
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Shen (changchun, China). The role of phonophoresis in patients with COPD: a randomized clinical trial. 176

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
ß-blockers in exacerbations of COPD: feasibility of a randomised controlled trial
Source: ERJ Open Res, 3 (1) 00090-2016; 10.1183/23120541.00090-2016
Year: 2017



Roflumilast in Asian patients with COPD: A randomised placebo-controlled trial
Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD
Year: 2011

Exacerbation action plans for patients with COPD and comorbidities: a randomised controlled trial
Source: Eur Respir J, 54 (5) 1802134; 10.1183/13993003.02134-2018
Year: 2019



Azithromycin for treatment of hospitalised COVID-19 patients: a randomised, multicentre, open-label clinical trial (DAWn-AZITHRO)
Source: ERJ Open Res, 8 (1) 00610-2021; 10.1183/23120541.00610-2021
Year: 2022



RCT Abstract - Randomized, double-blind, placebo-controlled, phase III clinical trial with MV130, a sublingual bacterial immunotherapy to prevent COPD exacerbations
Source: Virtual Congress 2021 – ALERT: COPD
Year: 2021



Cardiac impact of inhaled therapy in the largest randomised placebo-controlled trial in COPD history: have we reached the SUMMIT?
Source: ERJ Open Res 2016: 00055-2016
Year: 2016



A prospective randomised double-blind placebo controlled trial of venlafaxine in patients with stable chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2006; 28: Suppl. 50, 32s
Year: 2006

Umeclidinium in patients with COPD: a randomised, placebo-controlled study
Source: Eur Respir J 2014; 43: 72-81
Year: 2004



Clinical effectiveness of MDI-HFA-Modulite budesonide in the treatment of asthma – meta-analysis of randomised controlled trials
Source: Eur Respir J 2006; 28: Suppl. 50, 315s
Year: 2006

The evaluation of the efficacy and safety of phospholipids‘ inhalation in patients with bronchial asthma (BA): A prospective randomized placebo-controlled study
Source: Annual Congress 2012 - Asthma treatment: efficacy and safety
Year: 2012

A randomized, double-blind, placebo-controlled study to evaluate the role of formoterol in management of acute asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 498s
Year: 2006

Can simvastatin reduce COPD exacerbations? A randomised double-blind controlled study
Source: Eur Respir J, 58 (1) 2001798; 10.1183/13993003.01798-2020
Year: 2021



Efficacy and costs of telehealth for the management of COPD: PROMETE II, a multicentre, randomized controlled trial
Source: International Congress 2017 – New trends in pulmonary rehabilitation and chronic care
Year: 2017



Evaluation of ICS/LABA combination therapy on respiratory function in patients with asthma: Open-label, randomized, cross-over trial.
Source: International Congress 2018 – New developments in the treatment of asthma
Year: 2018


A randomised double-blind placebo-controlled trial of the effect of inhaled heparin on lung function, hyperinflation and exercise capacity in patients with COPD
Source: International Congress 2016 – Novel insights into the treatment of COPD
Year: 2016

Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial
Source: Eur Respir J, 59 (2) 2101471; 10.1183/13993003.01471-2021
Year: 2022



A double-blind randomised controlled trial of protein supplementation to enhance exercise capacity in COPD during pulmonary rehabilitation: a pilot study
Source: ERJ Open Res, 7 (1) 00077-2021; 10.1183/23120541.00077-2021
Year: 2021



Late Breaking Abstract - A randomised, double-blind, placebo controlled, clinical trial evaluating imatinib in patients with severe COVID-19
Source: Virtual Congress 2021 – Late breaking basic and translational science of SARS-Cov2 and COVID-19
Year: 2021



Applicability of randomized controlled trials (RCTs) results to real-life patients in COPD
Source: International Congress 2017 – Management of COPD
Year: 2017